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doi:10.1016/j.numecd.2012.01.007Abstract Background and aim: Experimentally uric acid may induce cardiomyocyte growth
and interstitial fibrosis of the heart. However, clinical studies exploring the relationship
between serum uric acid (SUA) and left ventricular (LV) mass yielded conflicting results.
The aim of our study was to evaluate the relationships between SUA and LV mass in a large
group of Caucasian essential hypertensive subjects.
Methods and results: We enrolled 534 hypertensive patients free of cardiovascular complica-
tions and without severe renal insufficiency. In all subjects routine blood chemistry, including
SUA determination, echocardiographic examination and 24 h ambulatory blood pressure (BP)
monitoring were obtained.
In the overall population we observed no significant correlation of SUA with LV mass indexed
for height2.7 (LVMH2.7) (r Z 0.074). When the same relationship was analysed separately in
men and women, we found a statistically significant correlation in female gender (r Z 0.27;
p < 0.001), but not in males (r Z 0.042; p Z NS). When we grouped the study population
in sex-specific tertiles of SUA, an increase in LVMH2.7 was observed in the highest tertiles in
women (44.5  15.6 vs 47.5  16 vs 55.9  22.2 g/m2.7; p < 0.001), but not in men.
The association between SUA and LVMH2.7 in women lost statistical significance in multiple
regression analyses, after adjustment for age, 24 h systolic BP, body mass index, serum creat-
inine and other potential confounders.
Conclusions: Our findings do not support an independent association between SUA and LV mass
in Caucasian men and women with arterial hypertension.
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+ MODELIntroduction Informed consent was obtained from each patient. TheHyperuricemia is particularly common in hypertensive
patients, especially in those with metabolic syndrome
(MetS) [1e4], where may be a marker of hyperinsulinemia
[5] and insulin resistance [5], as well as of renal dysfunction
[1,3,6,7] and diuretic use [1,3]. In some, but not in all,
studies [1,2,8] performed in hypertensive subjects, the
association between serum uric acid (SUA) and cardiovas-
cular (CV) events remained significant after adjustment for
potential confounding factors.
The development of left ventricular hypertrophy (LVH), in
hypertensive patients with high concentration of SUA may
potentially explain, at least in part, the enhanced CV risk
observed in these subjects, because LVH is a strong predictor
of CV events [9]. Indeed, uric acid is thought to induce
experimentally cardiomyocyte growth and interstitial fibrosis
of the heart, in part via activation of the renineangiotensin
system (RAS) [10,11] and in part by inducing endothelin-1
gene expression in cardiac fibroblasts [12].
However, clinical studies exploring the relationship
between SUA and left ventricular (LV) mass yielded con-
flicting results [8,13e22]. Moreover, in some studies
a significant effect of SUA on LV mass (LVM) was observed
only in women [14,16], while others described the oppo-
site [15].
The aim of our study was to evaluate in a large group of
Caucasian essential hypertensive subjects the relationship
between SUA and LVM and to assess the influence of gender,
if any, on this relationship.Methods
The population of this cross-sectional study was selected
from 646 hypertensive Caucasian patients consecutively
attending our Hypertension Unit.
The exclusion criteria were: secondary or malignant
hypertension, heart failure, positive history or clinical signs
of ischemic heart disease, cerebrovascular disease, severe
renal function impairment, defined by an estimated
glomerular filtration rate (GFR) <30 ml/min/1.73 m2, gout,
treatment with SUA-lowering medication (with the excep-
tion of losartan) in the last year, dyslipidemia requiring
pharmacological treatment, type 1 diabetes or type 2 dia-
betes requiring insulin therapy, major non cardiovascular
diseases.
Fifty-two subjects met these criteria and therefore were
not enrolled.
Of the remaining individuals 60 were also excluded,
because suboptimal echocardiographic tracings or fewer
than 80% valid ambulatory blood pressure monitoring
(ABPM) readings were obtained. Hence, the final statistical
analysis involved 534 patients.
Before entering the study, 311 hypertensive subjects
had been pharmacologically treated. These patients were
studied at least 2 weeks after the discontinuation of all
antihypertensive drugs.
All the participants to this study may be considered as
sedentary subjects.
Persons who reported smoking cigarettes regularly
during the past year were considered current smokers.Please cite this article in press as: Mule` G, et al., Absence of an inde
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Study design
After the period of pharmacological washout, clinic blood
pressure (BP) was recorded by a doctor, in the non-
dominant arm using the auscultatory method with
a mercury sphygmomanometer and appropriated cuff for
arm diameter, following the 2007 guidelines of the Euro-
pean Society of Hypertension (ESH) [23]. Three consecutive
measurements were taken at 2 min intervals and averaged.
The following morning, after an overnight fast of at least
12 h, blood samples were drawn to perform routine blood
chemistry.
Furthermore, 24 h ABPM and echocardiographic study
were carried out.
Measurements
Determination of routine biochemical parameters was
performed with standard techniques by using an auto-
analyser (ILab 300þ, Instrumentation Laboratory, Milan,
Italy).
Serum uric acid was measured using an uricase/peroxi-
dase method implemented in the above mentioned
autoanalyser.
Estimated GFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [24].
Low-density lipoprotein cholesterol (LDL) was calculated
by the Friedwald formula.
The presence of type 2 diabetes was defined as fasting
plasma glucose of 126 mg/dl or higher or use of oral
hypoglycemic agents.
The diagnosis of the MetS was based on the joint interim
statement of the International Diabetes Federation Task
Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of
Obesity [25].
A portable, non-invasive SpaceLabs 90207 recorder
(Redmond, Washington, USA) performed the 24 h ABPM.
M-mode measurements were taken with the American
Society of Echocardiography (ASE) recommendations [26].
LVM was determined using the ASE corrected cube-formula
[27]. It was indexed by both body surface area (LVMI) and
by height elevated by a power of 2.7 (LVMH2.7), in order to
provide a more stringent allowance for obesity [28].
A cut-off point of 51 g/m2.7 in either gender was set to
separate normal from LVH [29].
Left ventricular hypertrophy was defined also as
LVMI  125 g/m2 for men and  110 g/m2 for women, as
suggested by the 2007 guidelines of the ESH [23].
Statistics
The study population was separated into two groups of
male and female participants. We split also the study
population in sex-specific tertiles of SUA (division points for
females: 3.8 and 5 mg/dl; for males: 4.9 and 6 mg/dl), inpendent association between serum uric acid and left ventricular
Metabolism & Cardiovascular Diseases (2012), doi:10.1016/
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+ MODELpatients with and without MetS and in subjects with and
without LVH.
Normally distributed continuous variables are given as
means  SD. Categorical variables are presented as
percentages.
Normal distribution of the continuous variables was
assessed using the KolmogoroveSmirnov test and the
assumption of satisfactory Gaussian distribution was met
for all of the examined variables, except for duration of
hypertension, triglycerides, LVM, LVMI, LVMH2.7 and SUA
which showed a positive skewed distribution. Because the
application of non parametric tests to LVM, LVMI, LVMH2.7
and SUA or their mathematical transformations provided
similar results to those obtained using parametric tests or
untransformed data, we have used only the latter in this
paper. Conversely, duration of hypertension and triglycer-
ides, for their very high level of skewness, were expressed
as median and interquartile range and logarithmically
transformed before starting the statistical tests.
Differences between subgroups were evaluated using
one-way analysis of variance (ANOVA) and the independent-
sample Student’s t-test for continuous variables and the
chi-square test for the categorical variables.
Two-way ANOVA was used to assess the differences
regarding SUA in subjects with and without MetS on the
basis of gender.
Tukey post-hoc test was used to perform multiple
comparisons.
Adjustment for age and other potential confounders was
carried out by analysis of covariance (ANCOVA).
Univariate relations between SUA and LVM and of these
parameters with other variables in the overall population
and in either gender were tested by Pearson correlation
coefficients and linear regression analysis.
Linear multiple stepwise regression analyses were used
to explore the independent correlates of LVMH2.7 and of
LVMI in the overall population and in both sexes. Three
models were built. The first (model 1) included age, sex
(only in the whole population), 24 h systolic and diastolicTable 1 Demographics and clinical data of the overall study po
Overall study popul
(n Z 534)
Age, years 47.1  13.7
Known hypertension duration, monthsa 6 (2e13)
Previous antihypertensive treatment, % 58.2
Serum uric acid, mg/dl 5.07  1.5
Body mass index, Kg/m2 28.4  4.8
Waist circumference, cm 96.2  14
Glycemia, mg/dl 98.3  24.6
Total cholesterol, mg/dl 204.7  39.4
HDL cholesterol, mg/dl 46.1  10.7
LDL cholesterol, mg/dl 131.7  36.2
Triglycerides, mg/dla 118 (80e165)
Prevalence of diabetes, % 7.5
Serum creatinine, mg/dl 0.88  0.18
Estimated GFR, ml/min/1.73 m2 78.5  20.7
Current smokers, % 27.2
a Data of these variables, for their skewed distribution, were given
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logical treatment and SUA. Model 2 included SUA, the
covariates that had shown a significant association with LVM
in model 1 plus triglycerides, high density lipoprotein (HDL)
cholesterol and body mass index (BMI). Model 3 included
SUA, the covariates that had shown a significant association
with LVM in model 2 plus serum creatinine. Subsequently in
these models 24 h BPs, BMI and serum creatinine were
replaced respectively by clinic BPs, waist circumference
and estimated GFR. Finally, all these models were run again
after the exclusion of the 40 diabetic participants.
The null hypothesis was rejected at a two-tailed
p < 0.05.
The statistical analyses were performed using the
SYSTAT DATA software package, version 12 (Systat, San
Jose, CA, USA).Results
Table 1 summarises demographic and clinical data of the
overall population, subdivided according to gender.
The overall prevalence of MetS was 46.4%. It was higher
in females (51.3%) than in males (42.7%; p Z 0.05). SUA
values were higher in subjects with MetS than in those
without it, in the whole population (5.4  1.5 vs
4.8  1.4 mg/dl; p < 0.001), in men (5.9  1.3 vs
5.2  1.4 mg/dl; p < 0.001), and in women (4.9  1.3 vs
4.1  1.2 mg/dl; p < 0.001).
SUA levels did not differ in diabetic (4.8  1.5 mg/dl)
compared to non diabetic subjects (5.1  1.5 mg/dl;
pZ 0.33), in smokers (5.2  1.6 mg/dl) versus non smokers
(5.0  1.4 mg/dl; p Z 0.33), in never treated
(5.1  1.4 mg/dl) versus previously pharmacologically
treated patients (5.0  1.5 mg/dl; p Z 0.13). SUA
concentrations were also similar in subjects previously
treated with losartan (n Z 24; 5.0  1.6 mg/dl) versus the
remaining ones (5.1  1.4 mg/dl; p Z 0.73), as well as in
patients previously treated with thiazides (n Z 97) or looppulation and of the two groups divided according to gender.
ation Males Females p
(n Z 300) (n Z 234)
45.1  14 49.9  12.9 <0.001
5 (1e12) 6 (2e14) 0.091
50.7 67.9 <0.001
5.5  1.4 4.5  1.3 <0.001
28.4  4.2 28.5  5.5 0.812
99.5  11.7 92  15.5 <0.001
97.3  22.4 94.6  27.4 0.211
202.6  39 207.4  39.9 0.163
44.7  9.9 48.3  11.3 <0.001
130.2  36.5 133.8  35.7 0.254
128 (83e175.5) 108.5 (76149) 0.003
6.7 8.5 0.514
0.96  0.2 0.78  0.16 <0.001
70.5  16.6 88.9  20.9 <0.001
32.0 21.0 0.004
as medians and interquartile range.
pendent association between serum uric acid and left ventricular
Metabolism & Cardiovascular Diseases (2012), doi:10.1016/
4 G. Mule` et al.
+ MODELdiuretics (n Z 10), always in combination with other anti-
hypertensive drugs, when compared to the remaining
subjects (5.2  1.4 vs 5.0  1.4 mg/dl; p Z 0.19).
Clinic and 24 h BP values and main echocardiographic
parameters of the study population, analysed also on the
basis of gender, are reported in Table 2.
Table 3 shows some demographic and clinical charac-
teristics of the study population separated in sex-specific
tertiles of SUA. Prevalence of LVH and values of LVMI
and of LVMH2.7 increased in highest SUA tertiles only in
women.
Univariate analysis of correlation showed (see
Supplementary table S1) that among the whole group, SUA
was directly related to age, BMI, WC, sCreat, triglycerides,
IVS, PWT, LVIDD, RWT, LAD, and inversely related to HDL
cholesterol, and estimated GFR. In both sexes SUA was
correlated to BMI, WC, sCreat, estimated GFR, whereas
only in men it was positively related to total and LDL
cholesterol and inversely associated with HDL cholesterol.
Only in women SUA was correlated to age, IVS, PWT, RWT,
and LAD and E/A ratio. No significant correlation was found
between SUA and clinic or 24 h BPs in the overall study
population and in men and women separately analysed.
The Supplementary table S2 displays the univariate
correlations of LVMH2.7 and of LVMI with other variables.
In the whole study population, SUA did not significantly
correlate neither with LVMH2.7 (r Z 0.074, p Z 0.09;
Fig. 1), nor with LVMI (r Z 0.075; p Z 0.08). This was true
even when the relationships between these variables were
assessed by a non parametric test (Spearman’s correlationTable 2 Clinic and 24 h blood pressures and echocardiographi
groups divided according to gender.
Clinic systolic blood pressure, mmHg
Clinic diastolic blood pressure, mmHg
24 h systolic blood pressure, mmHg
24 h diastolic blood pressure, mmHg
End-diastolic left ventricular internal dimension (LVIDD), mm
End-diastolic interventricular septum thickness (IVS), mm
End-diastolic posterior wall thickness (PWT), mm
Myocardial relative wall thickness (RWT), %
Left atrial dimension (LAD), mm
Ejection fraction (EF), %
Early/late diastolic peak flow velocity (E/A) ratio
Left ventricular mass, g
Left ventricular mass indexed for height2.7, g/m2.7
Left ventricular mass index, g/m2
Prevalence of left ventricular hypertrophy (A), %
Prevalence of left ventricular hypertrophy (B), %
(A): Left ventricular hypertrophy was defined as LVMH2.7 > 51 g/m2.7
(B): Left ventricular hypertrophy was defined as LVMI  125 g/m2 for
(p Z 0.277 for left ventricular mass indexed for height2.7 and p Z 0.
a This difference disappeared after adjustment for age.
b Similar results were obtained by using KruskaleWallis test, instead
variables.
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p Z 0.06; r Z 0.083, p Z 0.055, respectively).
Similarly, SUA was not associated neither to LVMH2.7
(rZ 0.04, pZ 0.55), nor to LVMI (rZ 0.03, pZ 0.60) in
the subset (n Z 223) of patients never pharmacologically
treated with antihypertensive agents.
Taking each gender into consideration separately, we
found a significant correlation between SUA and LVMH2.7 in
women, but not in men (Fig. 1). Likewise, LVMI was
significantly associated to SUA in females (r Z 0.20,
p < 0.001), but not in males (r Z 0.07, p Z 0.10).
No difference was found regarding LVMH2.7 (49.8  18.8
vs 47.7  16.8 mg/dl; p Z 0.26) or RWT (39.4  8.8 vs
38.7  7.5%; p Z 0.41) in patients previously treated with
diuretics when compared to the remaining subjects.
In all the study subjects, those with LVH, defined as
a value of LVMH2.7 > 51 g/m2.7, showed slightly, but not
significantly, higher levels of SUA (5.3  1.7 vs 5.0  1.7;
p Z 0.07). Whereas in the group of male subjects the
concentration of SUA in the two subgroups with and without
LVH was virtually the same (5.5  1.7 vs 5.5  1.5;
p Z 0.97), in the group of women those with LVH had
greater values of SUA than women without LVH (4.9  1.3 vs
4.3  1.3; p < 0.001), but this difference became not
significant (pZ 0.75) after adjustment for age, sCreat, 24 h
systolic BP, BMI, triglycerides and previous antihypertensive
therapy.
Analogous results were obtained when LVH was defined
as LVMI  110 g/m2 in women and >125 g/m2 in men (data
not shown).c parameters of the overall study population and of the two
Overall study
population
(n Z 534)
Males
(n Z 300)
Females
(n Z 234)
p
159.1  21.5 157.1  20.4 161.0  22.6 0.037
94.6  13.7 96.0  13.8 93.1  13.4 0.015
137.6  12.7 136.0  12.7 139.1  12.6 0.005
85.7  10.7 87.2  10.4 84.1  10.9 <0.001
50.3  6.5 51.9  6.2 48.1  6.3 <0.001
10.4  1.9 10.7  1.9 9.9  1.9 <0.001
9.7  1.8 10  1.7 9.3  1.8 <0.001
39.0  8.2 38.8  7.6 39.3  8.9 0.443
36.1  5.6 36.9  4.8 35.1  6.3 <0.001
64.2  6.6 63.7  6.0 64.9  7.2 0.04
1.20  0.41 1.26  0.44 1.11  0.35 <0.001a
189  68 207.1  60 165.8  69 <0.0001
48.6  17.7 47.8  16.7 49.6  18.9 0.244b
102.1  35 105.7  34.8 97.3  34.7 0.006b
32.0 30.0 34.6 0.298
23.0 22.3 23.9 0.74
in either gender.
men and  110 g/m2 for women.
002 for left ventricular mass index).
of Student’s t-test, for the slightly skewed distribution of these
pendent association between serum uric acid and left ventricular
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Table 3 Descriptive characteristics of the patients on the basis of tertiles of serum uric acid and gender.
Males Females
I Tertile
(n Z 100)
II Tertile
(n Z 98)
III Tertile
(n Z 102)
p I Tertile
(n Z 78)
II Tertile
(n Z 77)
III tertile
(n Z 79)
p
Age, years 44.1  14.5 43.4  13.5 47.4  13.8 0.096 45.2  12.3 50.7  12.8x 53.3  12.3 <0.001
Known hypertension duration, months 4 (1.25e12) 5 (1.5e12) 6 (1e15) 0.337 5 (2e11.3) 5 (2e12.3) 9.5 (3e16.5) 0.092
Previous antihypertensive treatment, % 51 53.3 48.1 0.769 68.4 73 63.1 0.412
Body mass index, Kg/m2 27.2  3.5^^ 28.1  3.5* 29.7  5.1 <0.001 27.1  4.9^ 27.9  5.6* 30.1  5.6 0.002
Waist circumference, cm 96.5  8.9^^ 98.1  8.8^ 102.5  10.7 <0.001 87.8  13.1 89.8  14.5** 97.1  16.5 <0.001
Glycemia, mg/dl 98.7  32 96.2  12.4 97.0  17.8 0.525 96.8  30.1 102.1  30.8 99.6  21.1 0.525
Total cholesterol, mg/dl 194.3  39 207.7  40.2 206.1  37.1 0.578 203.6  35 208.3  37.5 210.1  45.8 0.578
HDL cholesterol, mg/dl 45.8  10.7 45.1  9.8 43.2  9.1 0.191 50.3  10.6 47.3  11.7 47.5  11.6 0.267
LDL cholesterol, mg/dl 123.9  36 131.9  36.6 135.0  36.5 0.107 130.8  31 136.3  38.0 133.9  36.9 0.066
Triglycerides, mg/dl 113 (75e154)* 142 (85e185)x 134 (93e185) 0.01 105 (79e13 103.5 (75e149) 115 (79e183.8) 0.018
Prevalence of metabolic syndrome, % 29.0^^ 44.6x 53.7 0.001 31.6^^ 54.1xx 66.7 <0.001
Prevalence of diabetes, % 9.0 3.2 7.4 0.261 9.2 10.8 6 0.535
Serum creatinine, mg/dl 0.93  0.17^^ 0.93  0.14* 1.01  0.18 <0.001 0.73  0.14 0.76  0.15* 0.83  0.18 0.001
Estimated GFR, ml/min/1.73 m2 73.8  18.9^^ 72.8  15.2* 65.5  14.1 <0.001 96.3  19.9 89.9  20.3* 81.5  19.9 <0.001
Current smokers, % 41.7 27.0 31.3 0.089 24 22 19.1 0.653
Clinic systolic blood pressure 157.2  19.3 159.9  22.1 154.3  19.8 0.154 157.0  19 160.9  19.4 165.1  27.3 0.072
Clinic diastolic blood pressure 95.2  13.6 97.7  15.9 95.1  11.9 0.359 92.0  13.1 94.9  14.1 92.5  13.1 0.358
24 h systolic blood pressure 136.8  11.4 136.3  13.1 135.0  13.5 0.626 138.3  11 139.7  14.6 139.4  12.1 0.772
24 h diastolic blood pressure 86.7  9.8 87.3  10.7 87.7  10.8 0.821 85.7  9.9 83.9  12.0 82.7  10.7 0.224
LV mass indexed for height2.7, g/m2.7 50.9  20.3 45.4  13 47.1  15.5 0.07 44.5  15.6 47.5  16 55.9  22.2 <0.001
LV mass index, g/m2 112.0  42.5 103.4  29 102.6  30.3 0.103 91.9  31.8 93.2  26.3 105.8  41.8 0.019
Myocardial relative wall thickness, % 37.9  7.0 39.6  8.5 38.9  7.4 0.32 38.6  9.9 38.3  7.5 41.0  8.1 0.11
Prevalence of LVH (A)a, % 35.4 23 31.1 0.18 21.4^^ 32.4 48.1 0.002
Prevalence of LVH (B)a, % 29 17.3 20.6 0.275 15.8** 18.9* 35.7 0.006
*p < 0.05 vs III Tertile; **p < 0.01 vs III Tertile; ^p < 0.005 vs III Tertile; ^^p < 0.001 vs III Tertile; xp < 0.05 vs I Tertile; xxp < vs I Tertile.
a For the definition of left ventricular hypertrophy (LVH) (A) and (B) see legend of Table 2.
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Figure 1 Scattergram showing the relationship between
serum uric acid and left ventricular mass indexed for height2.7
(LVMH2.7) in 534 essential hypertensive patients. The rela-
tionship was not statistically significant in the whole study
population (r Z 0.074; p Z 0.09) and in men (open circles)
(r Z 0.042; p Z 0.47). In women (open triangles) the same
relationship was positive and statistically significant
(r Z 0.271; p < 0.001). The calculated regression lines for
males (broken line) and females (solid line) are also shown. The
use of Spearman’s rank correlation analysis, instead of the
Pearson’s coefficient, yielded similar results (r Z 0.081,
p Z 0.06, in the whole population; r Z - 0.012, p Z 0.84, in
males; r Z 0.243, p < 0.001, in females).
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+ MODELMultiple linear regression analyses confirmed that SUA
was unrelated to LVMH2.7 in the whole study population
(p Z 0.78), in men (p Z 0.13) and in women (p Z 0.19)
(Table 3). Similarly, when in the multivariable model we
replaced the dependent variable LVMH2.7 with LVMI, this
latter was not independently associated with SUA (pZ 0.63
in the overall study population, p Z 0.12 in men and
p Z 0.40 in women).Table 4 Multiple regression models to assess the independen
(LVMH2.7) in female gender.
Model 1
Multiple R: 0.530
Adjusted multiple R2:
0.267
b p
Age 0.279 <0.001
24 h systolic blood pressure 0.369 <0.001
Serum uric acid 0.170 0.006
Previous antihypertensive
treatment
0.118 0.052
24 h diastolic blood pressure e NS
Known hypertension duration
(Log)
e NS
Body mass index
HDL cholesterol
Triglycerides (Log)
Serum creatinine
Model 1 includes the following covariates: age, 24 h systolic and dias
Model 2 includes the covariates significantly associated with LVMH2.7
includes the covariates significantly associated with LVMH2.7 in model
NS: not significant.
Please cite this article in press as: Mule` G, et al., Absence of an inde
mass in Caucasian hypertensive women and men, Nutrition,
j.numecd.2012.01.007The independent correlates of LVMH2.7 and of LVMI (age,
24 h systolic BP, serum creatinine, BMI) were the same in
the overall population, in men and in women.
Table 4 shows the results of multiple regression analyses
performed to assess the independent predictors of LVMH2.7
in the female group.
The inclusion into the multivariate models of clinic,
instead of the 24 h ambulatory BP readings, of WC instead
of BMI and of estimated GFR instead of sCreat did not
significantly modify the results. The same was true when
diabetic patients were excluded from the analysis.
The univariate associations observed in women between
SUA and RWT and between SUA and E/A ratio (Table S1)
disappeared after adjustment for age, 24 h systolic BP,
sCreat and BMI in multiple regression analyses.
Discussion
The most relevant result of this study is the absence of an
independent association between SUA levels and LVM,
regardless of the method of indexation. Even if in univar-
iate analyses, in the women group, SUA was closely related
to LVMH2.7 and to LVH, these associations lost statistical
significance after adjustment for many potential
confounders.
Our findings seem to be in contrast with experimental
studies that support a pathogenetic role of hyperuricemia
in the development of LVH. Previous reports have shown
that uric acid induces endothelial dysfunction and smooth
muscle cell proliferation by activating the RAS and inflam-
matory mediators such as tumor necrosis factor-alpha and
mitogen-activated protein kinases, which are known to
induce cardiac hypertrophy [1,10,11,30]. It has been also
reported that uric acid in vitro may increase endothelin-1t correlates of left ventricular mass indexed for height2.7
Model 2 Model 3
Multiple R: 0.566 Multiple R: 0.593
Adjusted multiple R2:
0.307
Adjusted multiple R2:
0.339
b p b p
0.263 <0.001 0.243 <0.001
0.289 <0.001 0.290 <0.001
0.120 0.046 e NS
e NS
0.228 <0.001 0.266 <0.001
e NS
e NS
0.216 <0.001
tolic BPs, duration of hypertension, previous treatment and SUA.
in model 1 plus triglycerides, HDL cholesterol and BMI. Model 2
2 plus serum creatinine. b: standardised regression coefficient e
pendent association between serum uric acid and left ventricular
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+ MODELgene expression in rat cardiac fibroblasts [12]. Indeed,
a significant positive relation between SUA and LVM or LVH
has been reported in some studies conducted in Asian
populations [8,13e15]. Kurata et al. reported that SUA
levels correlated positively with LVMI in male hypertensive
patients, but not in females [15]. In a smaller sample of
hypertensive subjects Matsumura et al found the opposite
[14]. Iwashima et al., in 619 hypertensive individuals,
showed that SUA was independently associated with LVMI
[8]. More recently, Mitsuhashi et al. reported that SUA was
positively associated with electrocardiographically diag-
nosed LVH in healthy Japanese men [13].
Moreover, Viazzi et al., in 425 middle-aged hypertensive
subjects, in univariate analysis, found a correlation
between SUA and LVMI, only in women, but the statistical
significance was just on the borderline level(p Z 0.04)
[16].In female gender, the probability of having LVH was
higher in subjects with elevated SUA levels in multiple
logistic regression analysis (pZ 0.03), but the multivariate
model did not include relevant covariates, known to be
associated with SUA or LVM, such as BMI and systolic BP
[16]. Finally, in 1225 newly diagnosed hypertensive
patients, SUA was related to LVMI in univariate analysis
[17]. However, this relationship became barely significant
after adjustment for multiple confounders, not including,
like in the previous study, BMI and systolic BP [17].
On the other hand, our results are in agreement with
several other studies conducted chiefly in hypertensive
populations [18e22]. Campo et al. found that hyperuri-
cemia was not an independent correlate of LVH in a study
sample of 677 male hypertensives [18]. Tsioufis et al.,
studied 842 patients with essential hypertension and found
that increased SUA levels were associated with micro-
albuminuria but not with LVH [19]. Similarly, Cuspidi et al.,
in a cross-sectional study of 580 untreated hypertensive
patients, failed to detect an independent association of
SUA with LVMI [20]. In another Italian study, including 400
essential hypertensives, SUA did not significantly correlate
with LVMH2.7 in multivariate analyses after taking into
account estimated GFR and indices of insulin resistance
[21]. More recently, in the general population of the
Vobarno Study, including 385 subjects from Northern Italy,
no independent association was observed between SUA and
LVM [22].
The discrepant conclusions of these studies may in part
be related to methodological differences and to heteroge-
neity in patient characteristics.
The conflicting findings about the relationships between
SUA and LVM seem in part to mirror the controversy on the
role of SUA as independent risk factor for CV morbidity and
mortality [1,2,8]. Up until today, it is still unclear whether
hyperuricemia has a causative role in CVD or, as has been
more often suggested, is simply a marker for other risk
factors, frequently associated with increased SUA levels,
such as hypertension, dyslipidemia, MetS and renal
dysfunction [1].
In agreement with the literature, our study confirms that
SUA concentrations are closely related to most components
of the MetS [1e6,16,19,20], including BMI or WC, triglyc-
erides, HDL cholesterol and with the MetS itself, as well as
with indices of renal function such as sCreat and estimated
GFR [1e3,6,7,15,21]. The association of SUA with thesePlease cite this article in press as: Mule` G, et al., Absence of an inde
mass in Caucasian hypertensive women and men, Nutrition,
j.numecd.2012.01.007parameters, most of which are well known correlates of
LVM, largely explained the significant univariate relation-
ships that we found in female gender between SUA and
cardiac hypertrophy. Indeed, we noticed that these asso-
ciations became not significant after adjustment for these
factors in multivariate analyses.
There are some potential limitations of our study.
The cross-sectional design of the present investigation
does not allow us to evaluate the impact of hyperuricemia
over time.
Furthermore, previous antihypertensive treatment that
had been stopped may have affected the results because of
the persisting influence on cardiac mass, even though
patients’ blood pressure and SUA levels may have returned
to control values. However, in the subset of hypertensive
patients who had never pharmacologically treated we
found results similar to those obtained in the whole pop-
ulation, with regard to LVM. Moreover, the absence of
association between SUA and LVM was confirmed, also
taking into account previous treatment in multivariate
analyses.
Finally, it is important to note that our results were
obtained in a selected population of Caucasian middle-aged
patients with mild-to-moderate essential hypertension,
without severe renal function impairment, free of cardio-
vascular diseases. Therefore, the conclusions of our study
cannot be extrapolated to non white populations and
caution is needed when applying the results of our inves-
tigation to different clinical settings.
In conclusion, our study showed that serum uric acid is
not independently associated with left ventricular mass,
regardless of the method of indexation, in both sexes.
On the basis of our findings, if hyperuricemia plays
a causative role in the pathogenesis of cardiovascular
disease, it is unlikely that this could be in part mediated by
the development of left ventricular hypertrophy.Acknowledgements
This work was supported in part by the Italian Ministry for
University and Scientific Research (MURST) grants (“ex 60%
quotas”).Appendix. Supplementary material
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.numecd.
2012.01.007.References
[1] Feig D, Kang DH, Johnson R. Uric acid and cardiovascular risk.
N Engl J Med 2008;359:1811e21.
[2] Strazzullo P, Puig JG. Uric acid and oxidative stress: relative
impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007;
17:409e14. doi:10.1016/j.numecd.2007.02.011.
[3] Lin CS, Hung YJ, Chen GY, Tzeng TF, Lee DY, Chen CY, et al. A
multicenter study of the association of serum uric acid, serum
creatinine, and diuretic use in hypertensive patients. Int J
Cardiol 2011;148:325e30. doi:10.1016/j.ijcard.2009.11.024.pendent association between serum uric acid and left ventricular
Metabolism & Cardiovascular Diseases (2012), doi:10.1016/
8 G. Mule` et al.
+ MODEL[4] Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I,
et al. Serum uric acid is a determinant of metabolic syndrome
in a population-based study. Am J Hypertens 2006;19:1055e62.
[5] Bonora E, Capaldo B, Cavallo Perin P, Del Prato S, De Mattia G,
Frittitta L, et al. Hyperinsulinemia and insulin resistance are
independently associated with plasma lipids, uric acid and
blood pressure in non-diabetic subjects. the GISIR database.
Nutr Metab Cardiovasc Dis 2008;18:624e31. doi:10.1016/j.
numecd.2007.05.002.
[6] Viazzi F, Leoncini G, Ratto E, Falqui V, Parodi A, Conti N, et al.
Mild hyperuricaemia and subclinical renal damage in
untreated primary hypertension. Am J Hypertens 2007;20:
1276e82.
[7] Cerasola G, Mule` G, Nardi E, Cusimano P, Palermo A, Arsena R,
et al. Clinical correlates of renal dysfunction in hypertensive
patients without cardiovascular complications: the REDHY
study. J Hum Hypertens 2010;24:44e50.
[8] Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y.
Uric acid, left ventricular mass index, and risk of cardiovas-
cular disease in essential hypertension. Hypertension 2006;47:
195e202.
[9] Vakili BA, Okin PM, Devereux RB. Prognostic implications of
left ventricular hypertrophy. Am Heart J 2001;141:334e41.
doi:10.1067/mhj.2001.113218.
[10] Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML.
Uric acid stimulates vascular smooth muscle cell proliferation
and oxidative stress via the vascular renineangiotensin
system. J Hypertens 2008;26:269e75.
[11] Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative
stress with an activation of the renin-angiotensin system in
human vascular endothelial cells as a novel mechanism of uric
acid-induced endothelial dysfunction. J Hypertens 2010;28:
1234e42.
[12] Cheng TH, Lin JW, Chao HH, Chen YL, Chen CH, Chan P, et al.
Uric acid activates extracellular signal-regulated kinases and
thereafter endothelin-1 expression in rat cardiac fibroblasts.
Int J Cardiol 2010;139:42e9. doi:10.1016/j.ijcard.2008.09.004.
[13] Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R,
Muramatsu T, et al. Uric acid and left ventricular hypertrophy
in Japanese men. Circ J 2009;73:667e72.
[14] Matsumura K, Ohtsubo T, Oniki H, Fujii K, Iida M. Gender-
related association of serum uric acid and left ventricular
hypertrophy in hypertension. Circ J 2006;70:885e8.
[15] Kurata A, Shigematsu Y, Higaki J. Sex-related differences in
relations of uric acid to left ventricular hypertrophy and
remodeling in Japanese hypertensive patients. Hypertens Res
2005;28:133e9.
[16] Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E,
et al. Serum uric acid and target organ damage in primary
hypertension. Hypertension 2005;45:991e6.
[17] Xaplanteris P, Vlachopoulos C, Vyssoulis G, Terentes-
Printzios D, Alexopoulos N, Lazaros G, et al. Uric acid levels,
left ventricular mass and geometry in newly diagnosed, never
treated hypertension. J Hum Hypertens 2011;25:340e2.
[18] Campo C, Ruilope LM, Segura J, Rodicio JL, Garcia-Robles R,
Garcia-Puig J. Hyperuricemia, low urine urate excretion andPlease cite this article in press as: Mule` G, et al., Absence of an inde
mass in Caucasian hypertensive women and men, Nutrition,
j.numecd.2012.01.007target organ damage in arterial hypertension. Blood Press
2003;12:277e83.
[19] Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D,
Zervoudaki A, et al. The controversial role of serum uric acid
in essential hypertension: relationships with indices of target
organ damage. J Hum Hypertens 2005;19:211e7.
[20] Cuspidi C, Valerio C, Sala C, Meani S, Esposito A, Zanchetti A,
et al. Lack of association between serum uric acid and organ
damage in a never-treated essential hypertensive population
at low prevalence of hyperuricemia. Am J Hypertens 2007;20:
678e85.
[21] Perticone F, Maio R, Ruberto C, Cassano S, Tripepi G,
Perticone M, et al. Kidney function and risk factors for left
ventricular hypertrophy in untreated uncomplicated essential
hypertension. Am J Kidney Dis 2008;52:74e84. doi:10.1053/j.
ajkd.2008.02.302.
[22] Salvetti M, Muiesan ML, Paini A, Agabiti Rosei C, Aggiusti C,
Stassaldi D, et al. Relationship between serum uric acid and
arterial stiffness and cardiac and carotid artery structure in
a general population in Northern Italy. J Hypertens; 2010:
e588e9.
[23] The Task Force for the Management of Arterial Hypertension of
the European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC). Guidelines for the management of
arterial hypertension. J Hypertens 2007;25:1105e87.
[24] Levey A, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF,
Feldman HI, et al. A new equation to estimate glomerular
filtration rate. Ann Intern Med 2009;150:604e12.
[25] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI,
Donato KA, et al. Harmonizing the metabolic syndrome:
a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart
Association; World Heart Federation; International Athero-
sclerosis Society; and International Association for the Study
of Obesity. Circulation 2009;120:1640e5.
[26] Sahn DJ, DeMaria A, Kisslo J, Weiman A. The committee on M-
mode standardization of the American society of echocardi-
ography. Circulation 1978;58:1072e3.
[27] Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E,
Pellikka PA, et al. Recommendations for chamber quantifica-
tion. Eur J Echocardiography 2006;7:79e108.
[28] de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ,
de Divitiis O, et al. Left ventricular mass and body size in
normotensive children and adults: assessment of allometric
relations and the impact of overweight. J Am Coll Cardiol
1992;20:1251e60. doi:10.1016/0735-1097(92)90385-Z.
[29] Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali GK.
Prediction of mortality risk by different methods of indexation
for left ventricular mass. J Am Coll Cardiol 1997;29:641e7.
doi:10.1016/S0735-1097(96)00552-9.
[30] Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T,
et al. Uric acid stimulates monocyte chemoattractant protein-
1 production in vascular muscle cells via mitogen-activated
protein kinase and cycloxygenase-2. Hypertension 2003;41:
1287e93.pendent association between serum uric acid and left ventricular
Metabolism & Cardiovascular Diseases (2012), doi:10.1016/
